Skip to main content
. 2009 Nov;1(3):183–205. doi: 10.1177/1758834009349119

Figure 1.

Figure 1.

Sorafenib (blue line) versus placebo (black line) TARGET study progression-free survival curves for second-line good- and intermediate-risk renal cell cancer. After Escudier et al. [Escudier et al. 2007]. With permission, New England Medical Society.